Hospital
Providence Saint John's Health Center
Providence Saint John's Health Center was paid $5.52M by Medicaid between Jan 2018 and Dec 2024, across 148 billing codes. Its largest line is 0450, Emergency room services — 21% of everything it billed.
33Billing provider infoPROVIDENCE SAINT JOHN'S HEALTH CENTER
SANTA MONICA, CA 90404
SANTA MONICA, CA 90404
33aNPI1124026273assigned 07/12/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.52M
24GClaims254,006
24DCodes billed148
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#217 of 410
Median peer was paid$6.90M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 37,351 | $700K | |
| 2019 | 36,661 | $693K | |
| 2020 | 28,236 | $563K | |
| 2021 | 32,304 | $692K | |
| 2022 | 31,714 | $898K | |
| 2023 | 44,480 | $1.03M | |
| 2024incomplete | 43,260 | $939K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 21% | 28,552 | 24,821 | $1.16M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 7.7% | 1,974 | 1,919 | $427K |
| 70450 | Computed tomography, head or brain; without contrast material | 6.2% | 3,929 | 3,754 | $344K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.8% | 2,026 | 1,963 | $322K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.5% | 2,031 | 1,916 | $304K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.7% | 6,509 | 6,088 | $260K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.4% | 9,762 | 9,019 | $189K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.4% | 2,575 | 2,241 | $134K |
| 80053 | Comprehensive metabolic panel | 2.3% | 16,075 | 14,560 | $124K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.2% | 1,708 | 1,581 | $122K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.2% | 4,685 | 4,211 | $119K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 2,002 | 1,939 | $102K |
136 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 18,506 | $91K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 4,293 | $86K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 1,434 | $79K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 958 | $78K |
| 71045 | Radiologic examination, chest; single view | 1.4% | 7,197 | $78K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.3% | 1,912 | $69K |
| 99199 | Unlisted special service, procedure or report | 1.2% | 1,709 | $68K |
| 99283 | Emergency room visit (moderate) | 1.2% | 1,551 | $67K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 3,606 | $67K |
| 93970 | 1.2% | 1,243 | $65K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 1,587 | $62K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 1,113 | $57K |
| Z7502 | <1% | 1,600 | $55K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 332 | $50K |
| 84484 | <1% | 7,339 | $49K | |
| 80306 | <1% | 3,764 | $47K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,561 | $45K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 839 | $43K |
| 83880 | <1% | 2,091 | $41K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,711 | $36K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,233 | $32K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 294 | $30K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 317 | $27K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,629 | $27K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,064 | $26K |
| 83690 | <1% | 5,293 | $25K | |
| 82330 | <1% | 1,988 | $23K | |
| 82077 | <1% | 1,963 | $22K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,183 | $22K |
| J3490 | Unclassified drugs | <1% | 3,705 | $21K |
| 81001 | <1% | 9,832 | $21K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,450 | $17K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 331 | $16K |
| 81025 | <1% | 3,775 | $16K | |
| 93971 | <1% | 257 | $16K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,244 | $14K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 910 | $13K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,078 | $13K |
| 87040 | <1% | 1,949 | $13K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,972 | $12K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,489 | $12K |
| 84145 | <1% | 978 | $12K | |
| 83605 | <1% | 1,768 | $12K | |
| 85610 | <1% | 3,923 | $12K | |
| 80179 | <1% | 846 | $10K | |
| 80143 | <1% | 857 | $10K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 80 | $10K |
| 80047 | <1% | 1,661 | $10K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,259 | $10K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,995 | $9K |
| 85730 | <1% | 2,291 | $9K | |
| 83735 | <1% | 2,152 | $8K | |
| 0250 | <1% | 8,686 | $8K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 144 | $7K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 300 | $7K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 332 | $7K |
| 0762 | <1% | 132 | $7K | |
| 73562 | <1% | 288 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 640 | $6K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,196 | $6K |
| 0301 | <1% | 100 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 310 | $5K |
| 85379 | <1% | 676 | $5K | |
| 87631 | <1% | 155 | $5K | |
| 73630 | <1% | 199 | $4K | |
| 80061 | Lipid panel | <1% | 1,208 | $4K |
| 85027 | <1% | 1,203 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,085 | $3K |
| 0270 | <1% | 1,773 | $3K | |
| 84439 | <1% | 988 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 332 | $3K |
| 87186 | <1% | 607 | $3K | |
| 80076 | <1% | 493 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 74 | $2K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 187 | $2K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 43 | $2K |
| 73610 | <1% | 107 | $2K | |
| 90715 | <1% | 70 | $2K | |
| 70496 | <1% | 13 | $2K | |
| 87077 | <1% | 454 | $2K | |
| Z7610 | <1% | 120 | $2K | |
| 73030 | <1% | 104 | $2K | |
| 82607 | <1% | 416 | $1K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 17 | $1K |
| 71250 | <1% | 24 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 84 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 84 | $1K |
| 73130 | <1% | 57 | $1K | |
| 87400 | <1% | 320 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 273 | $1K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 244 | $1K |
| 0510 | <1% | 188 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,617 | $1K |
| 82728 | <1% | 303 | $1K | |
| 96376 | <1% | 222 | $895.58 | |
| 85652 | <1% | 888 | $809.05 | |
| 87430 | <1% | 131 | $739.48 | |
| 86140 | <1% | 404 | $691.01 | |
| 85380 | <1% | 232 | $672.12 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 141 | $654.94 |
| 0324 | <1% | 41 | $638.72 | |
| 87081 | <1% | 171 | $617.83 | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 13 | $612.25 |
| 82550 | <1% | 119 | $573.26 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 128 | $543.74 |
| 86900 | <1% | 254 | $517.81 | |
| 83540 | <1% | 351 | $501.31 | |
| 83550 | <1% | 332 | $484.71 | |
| 99221 | <1% | 18 | $477.40 | |
| 86901 | <1% | 238 | $471.84 | |
| 84702 | <1% | 45 | $414.18 | |
| 84100 | <1% | 231 | $354.77 | |
| 96367 | <1% | 12 | $331.39 | |
| 84550 | <1% | 268 | $263.29 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 45 | $223.83 |
| 87205 | <1% | 107 | $211.64 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 71 | $198.81 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,675 | $189.41 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 19 | $185.28 |
| 0636 | <1% | 642 | $184.29 | |
| 86850 | <1% | 58 | $168.92 | |
| A4217 | Sterile water/saline, 500 ml | <1% | 30 | $152.46 |
| 84481 | <1% | 12 | $134.46 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 14 | $90.48 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 16 | $81.05 |
| A4649 | Surgical supply; miscellaneous | <1% | 312 | $65.30 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 12 | $61.04 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 25 | $52.23 |
| 87070 | <1% | 14 | $48.55 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 12 | $39.29 |
| 87147 | <1% | 14 | $25.44 | |
| 82570 | <1% | 13 | $5.18 | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 0% | 12 | $0.00 |
| 0258 | 0% | 24 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 39 | $0.00 |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY ENROLLMENTS)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.